Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.

This study provides Class III evidence that for patients with MS, while DMD exposure reduces the risk of infection-related hospitalizations, there are increased risks of infection-related physician visits and incident adverse events for select DMDs.